Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of TACE with durvalumab with or without bevacizumab versus placebo in locoregional hepatocellular carcinoma
jRCT2080224736Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Durvalumab plus TACE, Durvalumab plus bevacizumab plus TACE and Placebo plus TACE (3 arms). Started Jun 2019; status: completed.
02
Drugs
durvalumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080224736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224736.